Asia Pacific Viral Vector Manufacturing Market Report and Forecast 2024-2032

Asia Pacific Viral Vector Manufacturing Market Report and Forecast 2024-2032

Asia Pacific Viral Vector Manufacturing Market Report and Forecast 2024-2032

Asia Pacific Viral Vector Manufacturing Market Outlook

The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, with Asia Pacific holding a significant market share. The market is driven by the increasing investment in the biotechnology and pharmaceutical sectors. It is expected to grow at a CAGR of 23.4% during the forecast period of 2024-2032, with the values likely to attain USD 13.5 billion by 2032.

Key Takeaways

• Viral vectors form a crucial component in gene therapy and vaccine manufacturing processes. The growing demand for gene therapies and vaccines to tackle the rising burden of infectious diseases and chronic diseases in the Asia Pacific region is expected to drive the market demand.
• One of the major Asia Pacific viral vector manufacturing market trends is the increased mergers and acquisitions among the key market players to share resources and expertise. In November 2023 , Ajinomoto Co., Inc., a Japanese multinational biotechnology corporation, announced the acquisition of Forge Biologics Holdings, LLC in a deal worth USD 620 million to extend its capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing.
• In May 2023, CDMO Aurigene Pharmaceutical Services, a subsidiary of Indian multinational pharmaceutical company Dr. Reddy’s Laboratories, announced its plan to spend USD 40 million to build a production facility for viral vectors, therapeutic proteins, and antibodies. Such substantial investments to boost production capacity are poised to elevate market value.

Asia Pacific Viral Vector Manufacturing Market Analysis

Viral vectors act as an efficient gene delivery vehicle and are used to transfer genetic materials into cells. They are increasingly utilized by molecular biologists to manipulate a certain cell type or tissue to express therapeutic proteins. Viral vectors play a vital role in gene therapy and vaccine manufacturing processes due to their ability to transfer therapeutic genes or antigens into target cells. The growing demand for gene therapies and vaccines to tackle the rising burden of infectious diseases and chronic diseases is expected to drive the Asia Pacific viral vector manufacturing market growth in the forecast period.

One of the major market trends is the rising mergers and acquisitions among the key market players to share resources and expertise. In November 2023 , Ajinomoto Co., Inc., a Japanese multinational food and biotechnology corporation, announced the acquisition of Forge Biologics Holdings, LLC (a viral vector and plasmid CDMO) in a deal worth USD 620 million to extend its capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing. The agreement will strengthen Ajinomoto’s position as a contract development and manufacturing organization (CDMO) as well as diversify its portfolio of services for gene and cell therapy clients. The transaction was completed in December 2023 . The rise in such strategic partnerships is expected to bolster the Asia Pacific viral vector manufacturing market share in the coming years.

In Asia Pacific, several leading companies are actively investing in the expansion of their production capacities. In May 2023 , a leading contract research, development, and manufacturing organization (CDMO) Aurigene Pharmaceutical Services, a subsidiary of Indian multinational pharmaceutical company Dr. Reddy’s Laboratories, announced its plan to spend USD 40 million to build a production facility for viral vectors, therapeutic proteins, and antibodies, with the aim to offer integrated services from clinical research to commercial manufacturing for small and large molecules. The facility will be constructed at a biotech park in Hyderabad (India) called Genome Valley and is expected to be fully operational by the first half of 2024. Such substantial investments to boost production capacity are poised to elevate market value.

Asia Pacific Viral Vector Manufacturing Market Segmentation  

Market Breakup by Type

• Adenoviral Vectors
• Adeno-Associated Viral (AAV) Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others

Market Breakup by Application

• Gene Therapy
• Cell Therapy
• Others

Market Breakup by Type Therapeutic Area

• Oncological Disorders
• Neurological Disorders
• Metabolic Disorders
• Immunological Disorders
• Others

Market Breakup by End User

• Research Organizations
• Biotech and Pharmaceutical Companies
• Others

Market Breakup by Country

• China
• Japan
• India
• ASEAN
• Australia
• Others

Asia Pacific Viral Vector Manufacturing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Thermo Fisher Scientific
• Merck KGaA
• F. Hoffmann-La Roche AG
• Cobra Biologics
• VGXI, Inc.
• Kolon Life Science
• FUJIFILM Diosynth Biotechnologies
• Virovek
• Yposkesi
• Batavia Biosciences

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

• What is the Asia Pacific viral vector manufacturing market forecast outlook for 2024-2032?

The Asia Pacific viral vector manufacturing market is expected to be driven by the rising demand for the global viral vector manufacturing market, which is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and is likely to reach a market value of USD 13.5 billion by 2032.

• What are the major factors aiding the Asia Pacific viral vector manufacturing market demand?

The rising emphasis on the advancement of gene therapies and vaccines is fuelling the demand for the market.

• What are the major Asia Pacific viral vector manufacturing market trends?

One of the significant trends in the market is the increased mergers and acquisitions among the key market players to share resources and expertise. In November 2023, Ajinomoto Co., Inc., a Japanese multinational biotechnology corporation, announced the acquisition of Forge Biologics Holdings, LLC in a deal worth USD 620 million to extend its capabilities in adeno-associated virus (AAV) and plasmid gene therapy manufacturing.

• What is the market segmentation based on the type?

Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors, among others.

• What is the market breakup by therapeutic area?

By therapeutic area, the market is divided into oncological disorders, neurological disorders, metabolic disorders, and immunological disorders, among others.

• What are the major end users of the market?

End users of the market are research organizations, biotech, and pharmaceutical companies, among others.

• What are the applications of viral vector manufacturing?

Major applications of viral vector manufacturing include gene therapy, cell therapy, and vaccines.

• What is the market segmentation by countries?

The market segmentation by countries includes China, Japan, India, ASEAN, and Australia, among others.

• Who are the key players involved in the Asia Pacific viral vector manufacturing market?

The key players in the market are Thermo Fisher Scientific, Merck KGaA, F. Hoffmann-La Roche AG, Cobra Biologics, VGXI, Inc., Kolon Life Science, FUJIFILM Diosynth Biotechnologies, Virovek, Yposkesi, and Batavia Biosciences.

Meta description

Asia Pacific viral vector manufacturing market is poised for growth, driven by the expansion of the global market, which was valued at USD 2.6 billion in 2023, and is projected to grow at a CAGR of 19.74% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.